Legend Biotech Corp LEGN:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:25 PM EDT35.00
-0.98 (-2.72%)
-0.98 (-2.72%)Volume
23,949
Close
35.98-0.30 (-0.83%)
-0.30 (-0.83%)Volume
3,995,726
52 week range
16.24 - 45.30
- Open34.98
- Day High37.50
- Day Low34.35
- Prev Close36.28
- 52 Week High45.30
- 52 Week High Date07/23/25
- 52 Week Low16.24
- 52 Week Low Date02/04/26
Latest On Legend Biotech Corp
Key Stats
- Market Cap6.683B
- Shares Out185.74M
- 10 Day Average Volume3.07M
- Dividend-
- Dividend Yield-
- Beta0.36
Latest On Legend Biotech Corp
KEY STATS
- Open34.98
- Day High37.50
- Day Low34.35
- Prev Close36.28
- 52 Week High45.30
- 52 Week High Date07/23/25
- 52 Week Low16.24
- 52 Week Low Date02/04/26
- Market Cap6.683B
- Shares Out185.74M
- 10 Day Average Volume3.07M
- Dividend-
- Dividend Yield-
- Beta0.36
RATIOS/PROFITABILITY
- EPS (TTM)-1.61
- P/E (TTM)-22.35
- Fwd P/E (NTM)64.02
- EBITDA (TTM)-95.236M
- ROE (TTM)-25.20%
- Revenue (TTM)1.139B
- Gross Margin (TTM)54.99%
- Net Margin (TTM)-21.97%
- Debt To Equity (MRQ)40.23%
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
- Legend Biotech rises 29.5%TipRanks
Related Video
watch now
Profile
MORELegend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic...
Fangliang Zhang Ph.D.
Chairman of the Board
Ying Huang Ph.D.
Chief Executive Officer, Director
Carlos Santos Garcia
Chief Financial Officer
Address
2101 Cottontail Lane
Somerset, NJ
08873
United States